University Hospital of Ferrara
Cona, Ferrara, 44124, Italy
NCT Number: NCT02454491
Transradial approach (TRA) for cardiac catheterization and percutaneous coronary interventions (PCI) is increasingly being used worldwide. At the present is unknown the cocktail of agents necessary to minimize local access site complications. The investigators planned a prospective randomized clinical trial to test the superiority of verapamil vs. heparin in the reduction of access site related complications.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 4
Cona, Ferrara, 44124, Italy
Transradial approach (TRA) for cardiac catheterization and percutaneous coronary interventions (PCI) is increasingly being used worldwide in both elective and emergency procedures because it reduces net adverse clinical events, through a reduction in major bleeding and all-cause mortality, when compared to transfemoral approach. However, radial artery occlusion (RAO) after the procedure (the incidence of which varies from 1% to 10%) remains one of the major limitations of TRA.
The aim of the study is to assess the superiority of verapamil versus heparin in the access success during transradial percutaneous coronary interventions (PCI).
METHODS Patients referred to the cath-lab of the Cardiovascular Institute of the University Hospital of Ferrara, Italy, for coronary angiography were randomized in 2 groups with a computer-generated random sequence. The study is double-blind. In the first group, patients received intravenous heparin (5000 UI) immediately after a 6 F sheath insertion. In the second group, patients received Verapamil (5 mg) immediately after a 6 F sheath insertion. If after the start of the procedure a radial artery spasm (RAS) occurs, the operators can choose to use bail-out a local vasodilator therapy. After sheath removal, hemostasis was obtained using a TR band (Terumo corporation, Tokyo, Japan) with a plethysmography-guided patent hemostasis technique. Radial artery patency was evaluated at 24 hours (early RAO) and 30 days after the procedure (late RAO) by ultrasound.
The aim of the study is to demonstrate that verapamil administration is superior to heparin administration in the reduction of the combined endpoint (occurrence of radial artery occlusion (early RAO), access site complication, radial artery spasm (RAS) requiring local bailout use of vasodilatator)
RAO will be assessed by ultrasonography by independent expert reviewer blinded to randomization
The investigators defined access site complication the following items:
The investigators defined radial artery spasm any spasm occurring during the procedure requiring the administration of local vasodilatators to allow the procedure
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Patients admitted to hospital with diagnosis of acute coronary syndrome and stable coronary artery disease according current European guidelines and with clinical indication to coronary artery angiography.
Exclusion criteria
intraradial administration of heparin 5000 ui
intraradial administration of verapamil 5 mg
Time frame: 24 hours
occurrence of early radial artery occlusion, access site complication, radial artery spasm (RAS) that requires the bailout use of vasodilatator
Time frame: 24 hours
occurrence of each singular component of primary endpoint
Time frame: 30 days
occurrence of radial artery occlusion (late RAO)
Time frame: 30 days
reopening of the closed radial at 24 hours.
Time frame: 24 hours
assessment with questionnaires of the pain and satisfaction of patients
Time frame: 30 days
assessment with questionnaires of the pain and satisfaction of patients
University Hospital of Ferrara
Other
Comparison of VERapamil vs. Heparin Therapy on Procedural sUccess During Transradial Coronary Procedures (VERMUT Study)
Acronym: VERMUT
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05414851
Cardiovascular Diseases, Dyslipidemias
Webster, New York, United States
View Trial DetailsNCT04977011
Aberrant Motor Behavior in Dementia, Acid-Base Imbalance
Taoyuan, Taiwan
View Trial DetailsNCT03301246
Arterial Occlusive Diseases, Arteriosclerosis
Indianapolis, Indiana, United States
View Trial DetailsNCT01234870
Arterial Occlusive Diseases, Arteriosclerosis
Chicago, Illinois, United States
View Trial Details